$LAB Cashflow Statement | Understand Stock

$LAB

$0.62 +$0.02 (2.68%) Close

$LAB Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Operating activities
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Bargain purchase gain
Loss on forward sale of Series B Preferred Stock
Loss on Bridge Loans
Stock-based compensation expense
Amortization of acquired intangible assets
Depreciation and amortization
Accretion of discount on short-term investments, net
Unrealized loss on equity investments
Non-cash lease expense
Provision for excess and obsolete inventory
Lease amortization
Change in fair value of warrants
Impairment of intangible assets
Loss from extinguishment of debt
Loss on disposal of property and equipment
Amortization of debt discounts, premiums and issuance costs
Change in fair value of contingent consideration
Other non-cash items
Changes in assets and liabilities:
Accounts receivable, net
Inventory
Prepaid expenses and other assets
Deferred tax asset, non-current
Accounts payable
Accrued liabilities
Accrued compensation and related benefits
Deferred revenue
Operating lease liabilities
Other liabilities

Net cash used in operating activities
Investing activities
Cash and restricted cash acquired in the Merger
Acquisition of business, net of cash acquired
Purchases of investments
Proceeds from sale of investments
Proceeds from NIH Contract
Purchases of short-term marketable debt securities
Purchases of long-term marketable debt securities
Purchases of marketable equity securities
Purchase of convertible note receivable
Proceeds from sales and maturities of investments
Purchases of property and equipment
Net cash provided by investing activities

Financing activities
Proceeds from bridge loans
Proceeds from issuance of Series B Preferred Stock
Proceeds from advances under revolving line of credit
Proceeds from issuance of common stock, net of commissions
Proceeds from 2019 Notes issuance
Proceeds from term loan
Repayment of term loan and convertible notes
Payment of term loan fee
Payment of debt and equity issuance costs
Repurchase of common stock
Repayment of long-term debt
Proceeds from ESPP stock issuance
Proceeds from ESPP stock issuance and exercise of stock options
Payments for taxes related to net share settlement of equity awards and other
Proceeds from exercise of stock options
Net cash provided by (used in) financing activities

Effect of foreign exchange rate fluctuations on cash and cash equivalents
Net increase (decrease) in cash, cash equivalents and restricted cash
Cash, cash equivalents and restricted cash at beginning of period
Cash, cash equivalents and restricted cash at end of period
Supplemental disclosures of cash flow information
Equity consideration transferred in connection with business combinations
Cash paid for interest
(Cash paid) cash refund received for income taxes
Unpaid debt and equity issuance costs
Purchases of property and equipment included in accounts payable
Non-cash right-of-use assets and lease liabilities
Asset retirement obligations

Comments